Literature DB >> 11071481

Iatrogenic Creutzfeldt-Jakob disease at the millennium.

P Brown1, M Preece, J P Brandel, T Sato, L McShane, I Zerr, A Fletcher, R G Will, M Pocchiari, N R Cashman, J H d'Aignaux, L Cervenáková, J Fradkin, L B Schonberger, S J Collins.   

Abstract

The causes and geographic distribution of 267 cases of iatrogenic Creutzfeldt-Jakob disease (CJD) are here updated at the millennium. Small numbers of still-occurring cases result from disease onsets after longer and longer incubation periods following infection by cadaveric human growth hormone or dura mater grafts manufactured and distributed before the mid-1980s. The proportion of recipients acquiring CJD from growth hormone varies from 0.3 to 4.4% in different countries, and acquisition from dura mater varies between 0.02 and 0.05% in Japan (where most cases occurred). Incubation periods can extend up to 30 years, and cerebellar onsets predominate in both hormone and graft recipients (in whom the site of graft placement had no effect on the clinical presentation). Homozygosity at codon 129 of the PRNP gene is over-represented in both forms of disease; it has no effect on the incubation period of graft recipients, but may promote shorter incubation periods in hormone cases. Knowledge about potential high-risk sources of contamination gained during the last quarter century, and the implementation of methods to circumvent them, should minimize the potential for iatrogenic contributions to the current spectrum of CJD.

Entities:  

Mesh:

Year:  2000        PMID: 11071481     DOI: 10.1212/wnl.55.8.1075

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  107 in total

1.  Disease latency in Creutzfeldt-Jakob disease via dural grafting: a case report.

Authors:  C J Lang; J G Heckmann; V Querner; B Neundörfer; J Kornhuber; M Buchfelder; H A Kretzschmar
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

2.  [Variant Creutzfeldt-Jakob disease. Epidemiology, detection, diagnosis and prevention with special reference to minimizing risk of iatrogenic transmission by medical products, especially surgical instruments. Report of the Variant Creutzfeldt-Jakob Disease Task Force on this topic].

Authors: 
Journal:  HNO       Date:  2002-04       Impact factor: 1.284

3.  Transmission of prions.

Authors:  C Weissmann; M Enari; P-C Klöhn; D Rossi; E Flechsig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-14       Impact factor: 11.205

4.  [Decontamination and sterilization of surgical instruments in suspected Creutzfeldt-Jakob disease. Are we converting to the recommendations by the Robert Koch Institute?].

Authors:  A Tropitzsch; H P Zenner
Journal:  HNO       Date:  2004-10       Impact factor: 1.284

5.  Osseous regeneration in the presence of oxidized cellulose and collagen.

Authors:  G J Dias; P V Peplow; F Teixeira
Journal:  J Mater Sci Mater Med       Date:  2003-09       Impact factor: 3.896

6.  Ophthalmic surgery and Creutzfeldt-Jakob disease.

Authors:  P S-Juan; H J T Ward; R De Silva; R S G Knight; R G Will
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

Review 7.  Young onset dementia.

Authors:  E L Sampson; J D Warren; M N Rossor
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401

Review 8.  Prion diseases.

Authors:  R S G Knight; R G Will
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

9.  Abnormal prion protein in the retina of the most commonly occurring subtype of sporadic Creutzfeldt-Jakob disease.

Authors:  M W Head; A H Peden; H M Yull; D L Ritchie; R E Bonshek; A B Tullo; J W Ironside
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

10.  [The use of disposable instruments of a high performance polymer for tonsillectomy and adenoidectomy].

Authors:  P-S Mauz; A Tropitzsch; D Funk; M Dworschak; P K Plinkert
Journal:  HNO       Date:  2003-04-09       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.